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Smart polymerAbstract In the article, groups of multifunctional polymers used in drug dosage form technology
were classiﬁed and evaluated. These compounds, in addition to their basic function as excipients,
may have additional properties, e.g. stimuli sensitivity, enzyme inhibition, intestinal epithelium
penetration enhancement, efﬂux pump inhibition, taste-masking, pharmacological activity and
the ability to interact with enzymes responsible for drug metabolism. While classifying speciﬁc
groups of multifunctional polymers, special emphasis was placed on the advantages of using them
when designing new drug. Such advantages include, i.a., increasing substance bioavailability,
improving substance stability during formulation and the possibility of obtaining forms of con-
trolled or localized release to a speciﬁc site in the organism.
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An important factor that inﬂuences the progress of potential
new drug carriers is the development of excipients which
have properties that may, depending on therapeutical needs,
enhance the bioavailability and stability of the drug, as well
as enable the construction of drug forms of controlled or
localized substance release (Koo, 2011; Aleeva et al., 2009;
Sene et al., 2004). Excipients are deﬁned as inactive ingredi-
ents which are mixed with active pharmaceutical ingredients
(API) in order to create a drug product that is ready for
speciﬁed use (Koo, 2011). Although these substances are
included in the inactive ingredients list put together by the
FDA, they usually have well deﬁned functions in a drug
product (Deepak and Gaurav, 2013). Modern achievements
in drug dosage form technology are based to a large extent
on employing macromolecular compounds, which, apart
from their basic function as excipients (i.e. performing vari-
ously as a tablet binder, lubricant, anti-adhesive agent, agent
which prevents too rapid decomposition, tablet disintegrant,
ﬁlling agent, coating agent, solubilizing agent, hydrophiliza-
tion agent, viscosity enhancer, stabilizer in disperse systems,
emulsifying agent, gelling agent, etc.), can also perform
other additional functions in drug forms (Aleeva et al.,
2009; Deepak and Gaurav, 2013). Polymeric excipients con-
stitute a very large and varied group of substances, including
macromolecular compounds of natural origin, e.g., sodium
alginate, gelatin, chitosan and cellulose derivatives; semisyn-
thetic polymers, e.g., cellulose derivatives; synthetic poly-
mers, e.g., polyethylene glycols, poloxamers, polylactides,
polyamides, acrylic acid polymers, etc.; and fermentation
products, e.g., xanthan gum (Sene et al., 2004; Ogaji
et al., 2012). These polymers are employed in drug dosage
forms administered through every possible route: orally, par-
enterally, nasally, intravaginally, rectally, inhalationally, on
the oral mucosa, topically and in ophthalmic preparations
(Mansour et al., 2010).
Multifunctional polymers are macromolecular com-
pounds which, according to deﬁnition, apart from their
basic function, may have additional properties that have
already been described in the literature, e.g., sensitivity
to stimuli, mucoadhesion, inhibition of enzymes, intestinal
epithelium penetration enhancement, efﬂux pump inhibi-
tion, increased buffer capacity, sorptive properties, taste-
masking ability, pharmacological activity and the ability
to form conjugates or interact with enzymes responsible
for drug metabolism. In this article, the groups of these
polymers which are employed in pharmaceutical technology
will be evaluated.2. Polymers sensitive to stimuli
One large group of macromolecular compounds is the so-
called smart polymers or stimuli-sensitive polymers. These poly-
mers are sensitive to physical stimuli, exhibiting changes in
their physicochemical properties as a reaction to small changes
in their surrounding environment, e.g., temperature, pH, ultra-
sounds, light, electric ﬁelds, and mechanical stress. They are
also sensitive to chemical stimuli (e.g. pH, ionic strength)
and biological stimuli (e.g., the presence of substances includ-
ing, i.a., enzymes and biomolecules) (Almeida et al., 2012; Kim
et al., 2009; Qiu and Park, 2012). The ability of polymers to
produce fast microscopic changes in their structure in response
to stimuli is rendered through changes to their shape, surface
properties and solubility, or through sol–gel phase transition,
which is employed in constructing drug carriers sensitive to
stimuli (Jeong and Gutowska, 2002). The signal may be cre-
ated artiﬁcially by ‘‘external’’ sources or may result from
changes in the ‘‘internal environment’’, e.g. accompanying cer-
tain pathophysiological states. Many monomers may be
characterized by sensitivity to certain stimuli; however, every
monomer can create homopolymers that are sensitive to a
speciﬁc signal, or copolymers that react to many stimuli
(Kim et al., 2009). The diversity of macromolecular com-
pounds constituents and methods of their synthesis enable
polymers to be modiﬁed and the creation of carriers sensitive
to speciﬁed stimuli in a narrow scope of changes.
Consequently, these intelligent polymers can be used to con-
struct more precise and programmed drug delivery systems.
The stimuli cause a reaction by changing the molecular inter-
actions between the polymer and solvent or between polymer’s
chains. Variations of these behaviours may include changes in
the polymer’s solubility, hydrophilic/hydrophobic balance and
conformation. Tables 1 and 2 show the examples of polymers
sensitive to speciﬁed stimuli and the possibilities of employing
these compounds in drug delivery systems, respectively.
Thermosensitive polymers are macromolecular compounds
which exhibit temperature dependence of the sol–gel transition
in water solutions. The transition in these systems from a vis-
cous liquid into elastic form takes place when exposed to a
lower critical solution temperature (LCST) as a result of a fast
viscosity increase (Jeong et al., 2002). In solutions of ther-
mosensitive macromolecular compounds, the increase of tem-
perature to LCST causes an entropy increase (DS> DH)
and a decrease in the free energy of binding (DG< 0), which
facilitates the replacement of the interactions between polymer
chain and solvent molecules by intra- and interchain
hydrophobic interactions and intra- and intermolecular hydro-
gen bonds (Bromberg and Ron, 1998).
Table 1 Examples of intelligent polymers (Almeida et al.,
2012; Schmaljohann, 2006; Aguilar et al., 2007; Jeong et al.,
2002; Xu et al., 2013; Priya et al., 2014).
Type of
stimulus
Polymers
pH pH responsive dendrimers i.e. poly-amidoamide
(PAMAM), dendrimers, poly(propyleneimine)
dendrimers, Poly(L-lisine) ester,
Poly(hydroxyproline), Poly(propyl acrylic acid),
Poly(methacrylic acid), Carbopol, Polysilamine,
Eudragit S-100, Eudragit L-100, Chitosan,
Poly(methacrylic acid) (PMMA), PMAA-PEG
copolymer, Maleic anhydride (MA), N,N-
dimethylaminoethyl methacrylate (DMAEMA)
Temperature Poloxamers (Pluronics), Prolastin, Poly(N-
substituted acrylamide),
Poly(organophosphazene), cyclotriphosphazenes
with poly(ethyleneglycol) and amino acid esters,
block copolymers of poly(ethylene glycol)/
poly(lactic-co-glycolic acid), Poly(ethylene glycol)
(PEG), Poly(propylene glycol) (PPG), PMAA,
Poly(vinyl alcohol) (PVA), various silk-elastin-like
polymers, Poly(silamine), Poly(vinyl methyl ether)
(PVME), Poly(vinyl methyl oxazolidone)
(PVMO), Poly(vinyl pyrrolidone) (PVP), Poly(N-
vinylcaprolactam), poly(N-vinyl isobutyl amid),
poly(vinyl methyl ether), poly(N-
vinylcaprolactam) (PVCL), Poly(siloxyethylene
glycol), poly(dimethylamino ethyl methacrylate),
triblock copolymer poly(DL-lactide-co-glycolide-
b-ethylene glycol-b-DL-lactide-co-glycolide)
(PLGA-PEG-PLGA), Cellulose derivatives,
Alginate, Gellan, Xyloglucan
Magnetic ﬁeld Poly(N-isopropylacrylamide) (PNIPAAm)
hydrogels containing ferromagnetic material
PNIPAAm-co-acrylamide
Electrical
signals
Chitosan, Sulfonated polystyrenes,
Poly(thiophene)s, Poly(ethyloxazoline)
Ions Sodium alginate (Ca2+), Chitosan (Mg2+)
Photosensitive Modiﬁed poly(acrylamide)s
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groups: polymers whose phase transition is based on LCST,
polymers whose sol–gel transition is connected with the exis-
tence of amphiphilic balance, biopolymers and artiﬁcial
polypeptides (Aguilar et al., 2007). The thermosensitive syn-
thetic polymers characterized by phase transition in LCST
include poly(N-isopropylacrylamide) (PNIPAAm), poly(N-
vinyl isobutyl amid), poly(vinyl methyl ether), poly(N-vinyl-
caprolactam) (PVCL) and poly(dimethylamino ethyl
methacrylate). The amphiphilic macromolecular compounds
include mostly three-block copolymers built of poly-
oxyethylene and polyoxypropylene (PEO-PPO-PEO) and
copolymers created as a result of replacing the PPO part in
macromolecule structure with other blocks, i.e., poly(1,2-oxy-
butylene) (PBO), poly(L-lactic acid) (PLLA) or poly(lactide-
co-glycolate) (PLGA) (Schmaljohann, 2006). Polysaccharides
of thermosensitive properties are cellulose derivatives: ethyl-
cellulose, hydroxyethyl cellulose (HEC) and ethyl hydrox-
yethyl cellulose (EHC), natural polysaccharides, e.g. agarose,
amylose, amylopectin, carrageenan, gellan and its derivative,
benzyl ester, creating in water solutions a double spiralstructure stabilized by hydrogen bonds. Artiﬁcial polypeptides,
e.g. elastin-like polymer (ELP) or silk-elastin-like block
copolymers (SELPs), are polymers that dissolve in water below
the phase transition temperature, forming a gel after it is
exceeded as a result of desolvation and aggregation of the
polymer’s subunits (Aguilar et al., 2007; Chilkoti et al., 2002).
Many examples can be found among numerous publica-
tions describing the application of temperature-sensitive poly-
mers in orally administered drug delivery systems, which
brings many additional advantages. In drug dosage form tech-
nology such advantages may be realized by employing the
copolymers of polyacrylic acid and poloxamer, macromolecu-
lar compounds forming an in situ gel in the gastroesophageal
reﬂux therapy or, in the case of oral administration of peptide
drugs, maintaining the stability in the above-mentioned car-
riers during their passage through the stomach. The micro-
spheres or beads described by Serres et al. (1996) and
Ramkissoon-Ganorkar et al. (1999), obtained using the
copolymer of poly-N-isopropylacrylamide with butyl-
methacrylate and acrylic acid P(NIPAM-co-BMAco-AAC)
in the alkaline environment of intestines, were subjected to dis-
integration and released active substances, e.g. calcitonin and
insulin.
Another beneﬁt of using thermosensitive polymers in drug
carriers is the possibility of achieving a greater concentration
of the drug, e.g. in the rectal cavity, and the advantageous
decrease of this concentration in the serum. This was achieved
in the case of administrating mitomycin in a xyloglucan-based
carrier. The release of the drug regulated through changes in
body temperature was, in turn, proposed by Csoka et al.
(2007), who designed a thermosensitive system for transdermal
application of the drug based on a multifunctional polymer –
hydroxypropyl methylcellulose. The sensitivity of the designed
carrier to temperature changes was additionally modulated
through introducing sodium chloride, potassium chloride or
sodium bicarbonate in different concentrations to the carrier.
Adding 8% potassium chloride to the formulation enabled,
depending on the applied temperature, various release speeds
of diclofenac sodium salt to be obtained. At 40 C, this
accessibility was about 3 times higher in comparison with an
examination conducted at 25 C (Csoka et al., 2007). On the
basis of thermosensitive polymers, e.g. poly(N-isopropylacry-
lamide), Pluronic and xyloglucan, modern ophthalmic drug
forms may also be constructed. Due to the existence of numer-
ous defence barriers in the eye, its limited capacity and the
poor ability of liquid and semi-solid preparations to stay in
the area of the defence apparatus and anterior segment of
the eyeball, it may be possible to increase the efﬁciency of
the therapy through employing gels formed in situ after appli-
cation. This enables the form to stay longer on the surface of
the eye and the longer contact of the water and active sub-
stances it contains with eye epithelium (Hsiue et al., 2002;
El-Kamel, 2002; Miyazaki et al., 2001; Hongyi et al., 2006).
Similar to the temperature-sensitive polymers described above,
pharmaceutical technology macromolecular compounds which
react to the change of environmental pH are being employed.
This is particularly relevant because of the existence of areas of
different pH values in the organism (Table 3).
Examples of pH-sensitive polymers applied in pharmaceuti-
cal formulations include poly(acrylic acid), poly(methacrylic
acid) and poly(2-ethylacrylic acid), in which the carboxyl
group remains non-ionized and keeps the drug in the carrier
Table 2 Examples of application of polymers sensitive to stimuli in drug delivery systems (Kim et al., 2009; Priya et al., 2014).
Stimulus Polymer Application
Temperature Poly(N-isopropylacrylamide) Hydrogel, doxorubicin release
Ultrasound Polyanhydride, polyglycolide, polylactide
poly(hydroxyethyl methacrylate-co-N,N0-
dimethylaminoethyl methacrylate)
Ultrasound-enhanced biodegradation
Ultrasound-enhanced drug release rate
Magnetic
ﬁeld
Poly(ethylene-co-vinylacetate) Prompted BSA release from matrix magnetic ﬁeld
Oxidation PEG-b-poly(propylene sulphide)-b-PEG Oxidation-sensitive polymer vesicle disintegration
Light Poly(N,N-dimethylacrylamide-co-4-phenyl-azophenyl
acrylate)
Photo-sensitive active site-gating of streptavidin
Poly(N,N-dimethyl acrylamide-co-4-phnyl-azophenyl
acrylamide)
Electricity Poly(ethylenediamine-co-1,10-bis(chloro-carbonyl)decane)
polyethyloxazoline/poly(methacrylate)
Electric-sensitive capsule
Electrically erodible matrix for insulin delivery
Mechanical
stress
Dihydrazide-crosslinked polyguluronate poly(methyl
methacrylate)/poly(vinyl alcohol) or/cellulose ether
Pressure-sensitive hydrogel
Pressure-sensitive adhesive
pH Poly(acrylic acid)-g-PEG Oral insulin delivery
PEG-b-poly(L-histidine) Doxorubicin release
Poly(n-isopropylacrylamide-co-propylacrylic acid-co-
butylacrylate) alginate and chemically modiﬁed
carboxymethyl chitosan
Fibroblast growth factor: improvement of angiogenesis,
providing the advantage of acidic microenvironment of ischaemic
myocardium
Protein drug for oral delivery: protecting the drug from the harsh
acidity of stomach with potential release in the intestine
Ionic
strength
Poly(NIPAAm-co-benzo-18-crown[6]-acrylamide) Ba2+-sensitive membrane pore
Enzymes aPEG-peptide linker-doxorubicin Doxorubicin release by lysosomal enzyme-mediated peptide
degradationaPoly(N-(2-hydroxypropyl)methacrylamide)-peptide linker-
doxorubicin
Biomolecules PEO-b-poly(2-glucosyloxyethyl acrylate) Glucose-sensitive micelle for insulin delivery
Thiolate PEG-b-poly(L-lysine) Glutathione-sensitive micelle for anti-sense DNA delivery
bPoly(RCOOH-co-butyl acrylate-co-pyridyl disulphide
acrylate)
Glutathione- and pH-sensitive copolymers for
oligodeoxynucleotide delivery
a Peptide linker = GFLG.
b R = –CH3, –CH2CH3, or –CH2CH2CH3.
Table 3 The pH of chosen tissues and compartments of the
organism (Almeida et al., 2012).
Tissue/cell compartment pH
Blood 7.35–7.45
Stomach 1.0–3.0
Duodenum 4.8–8.2
Colon 7.0–7.5
Early endosome 6.0–6.5
Late endosome 5.0–6.0
Lysosome 4.5–5.0
Golgi complex 6.4
Tumor – extracellular medium 7.2–6.5
528 B. Karolewiczstructure in the acid-pH stomach environment (Aguilar et al.,
2007; Xu et al., 2013). On the other hand, in the alkaline or
neutral environment of the small intestine these groups get ion-
ized, and the polymer swells due to their electrostatic repulsion
while simultaneously releasing the drug to the environment.
Carriers designed on the basis of polycationic polymers, i.e.
poly(vinylamine), poly(2-vinylpyridine), poly(4vinylpyridine),
poly(N,N-dimethylaminoethyl methacrylate), poly(N,N-di-
ethylaminoethyl methacrylate), poly(N,N-diakyl aminoethyl
methacrylates), poly(lysine), poly(ethylenimine) and chitosanexhibited other behaviours in different pH environments
(Aguilar et al., 2007). In neutral or alkaline pH, amine groups
of these polymers exist in a non-ionized form and keep the
drug in the carrier structure; when the pH value decreases
below pKa, these groups become ionized, and the polymer
net swells due to the electrostatic repulsion of the neighbouring
positively charged groups, thus releasing the drug to the
environment (Almeida et al., 2012).
3. Mucoadhesive polymers
Mucoadhesive polymers constitute an important group of
excipients employed when designing drug forms such as
tablets, capsules, powders, multi-compartment systems, thin
strips, inserts, solutions, suspensions, gels and foams. These
forms are applied, i.a., on the oral cavity mucosa, sublingually,
orally, intravaginally, rectally, nasally and ophthalmically.
Their use in these forms prolongs the time that the drug form
resides at the site of drug absorption, thus ensuring a high con-
centration gradient of the released substance, its protection
from enzymatic degradation and, as a result, improved absorp-
tion. Polymers, because of the kind of created mechanism
responsible for mucoadhesion, are classiﬁed as being in the
group of noncovalently and covalently bonding macromolecu-
lar compounds. In the case of noncovalently bonding
A review of polymers as multifunctional excipients 529polymers, this mechanism is a result of creating hydrogen
bonds, ionic interactions and van der Waals forces, while in
the second polymer group it results from forming covalent
bonds between mucus and the polymer (Vigl, 2009). The
noncovalently bonding mucoadhesive polymers include anio-
nic, cationic and nonionic compounds. The interaction of
anionic polymers, e.g. polyacrylates, carboxymethyl cellulose
sodium salt and alginates, thiolated alginates, pectins, poly-
acrylates, sodium carboxymethyl cellulose, xanthan gum and
hyaluronic acid with mucus, takes place through forming
hydrogen bonds between carboxylic polymer groups and
mucus glycoproteins hydroxyl groups (Nallathambi and
Gopal, 2013). However, in this case the environmental pH
strongly inﬂuences the swelling of polymers. At low pH, swel-
ling is minor due to the protonation of carboxylic polymer
groups, whereas an increase of acidity in the environment
may lead to major swelling and the loss of mucoadhesion.
At low pH values in the stomach the alginate shrinks and turns
into insoluble acid, which results in the lack of release of the
drug administered in the system designed on this basis.
Passing further along the gastrointestinal tract, the polymer
becomes soluble and viscous, which enables a controlled drug
release to be achieved. Thiolation of alginate improves not
only its mucoadhesion, but also the swelling and its cohesive-
ness, thus increasing the stability of the network. Modifying
polymers through introducing long hydrophobic alkyl chains
to its structure leads in turn to increased drug encapsulation,
but disables the fast dissolution and thus sustained substance
release is obtained. Cross-linking the alginate or complexing
it with other polymers, e.g. pectins, chitosans or Eudragit,
increases the encapsulation efﬁciency, limiting the leaching of
the drug through the pores of the obtained alginate hydrogel
(Vigl, 2009).
The most frequently used cationic mucoadhesive polymers
include chitosan, aminodextran, diethylaminoethyl (DEAE)-
dextran and polylysine, which – due to the presence of amine
groups – interact with anionic substructures of sialic acid resi-
dues in the mucus layer (Nallathambi and Gopal, 2013).
Chitosan is quickly hydrated in low pH environments, e.g. gas-
tric acid pH, does not swell and does not exhibit greater
mucoadhesion in pH above 6.5. Mucoadhesive polymers also
include macromolecular nonionic compounds, i.e. cellulose
derivatives: hydroxypropyl cellulose (HPC), HEC, polyvinyl
alcohol and polyvinylpyrrolidone, macrogols, whose proper-
ties depend to a small extent on the pH environment and con-
centration of electrolytes in a solution. The main mechanism of
mucoadhesion in their case seems to be only the physical inter-
penetration and the later entanglement of polymer chains.
Some of these polymers, e.g. polyethylene oxide, may addition-
ally form hydrogen bonds, which, however, play a small role in
the mucoadhesion mechanism.
Thiomers are also counted among mucoadhesive polymers
forming covalent bonds. They are obtained by attaching thiol
groups of ligands to polymers, i.e. polyacrylates or chitosan
(Kafedjiiski and Franzens, 2004). Thiomers are covalently
anchored in the mucus layer, which results from forming disul-
phide bonds with cysteine-rich subdomains of secreted
glycoproteins in the replacement thiol/disulphide reaction
and/or oxidation reactions. The formed connections are stron-
ger than non-covalent bonds, i.e. hydrogen bonds or van der
Waals forces, and display signiﬁcantly larger mucoadhesion
in comparison with corresponding non-modiﬁed polymers(Kawadkar and Chauhan, 2010; Kushawaha et al., 2010;
Mythri et al., 2011; Kast and Bernkop-Schnurch, 2002;
Sreenivas and Pai, 2009).4. Polymers inhibiting action of enzymes
Macromolecular compounds with enzyme-inhibiting proper-
ties include polyacrylic acid, sodium alginate, carboxymethyl
cellulose, chitosan citrate, thiomers, polymer-enzyme inhibitor
conjugates, chitosan-EDTA conjugates and the copolymers
poly(methacrylic acid) and poly(ethylene glycol) (P(MAA-g-
EG) or starch and polyacrylic acid (Bernkop-Schnurch, 2000;
Bonferoni et al., 2008; Lv et al., 2014; Nakamura et al.,
2008). Enzyme-action inhibition may result from binding
Ca2+ and Zn2+ ions, which play a key role in the thermody-
namic enzyme stability, or from the enzyme–polymer interac-
tion decreasing the free enzyme concentration as well as
from a fall in the pH value below the optimal level required
for its activity (Kawadkar and Chauhan, 2010; Lv et al.,
2014). Acrylic acid polymers inhibit the proteolytic enzymes
action by binding the metals’ ions, the indispensable compo-
nents of these proteins’ structure, which may lead to con-
formational changes and may induce their autolysis.
Moreover, it is presumed that acrylic acid polymers bind tryp-
sin, contributing to the inactivation of the enzyme. In the case
of chitosan, the polymer itself exhibits weak enzyme-inhibiting
properties and only its conjugation with an enzyme-inhibitor,
i.e. the Bowman-Birk inhibitor, elastinal or complexing with
EDTA, leads to enzyme-inhibition (Guggi and Bernkop-
Schnurch, 2003). Proteases-inhibitors of the Bowman-Birk
family have a low molecular mass, usually 600–16,000 Da,
and are polypeptides that contain on average 60–90 amino
acids, maintaining their compact structure due to the presence
of a signiﬁcant number of disulphide bonds. Attaching a tryp-
sin-inhibitor (Bowman-Birk) to soybean polyacrylate, as in the
case of chitosan, improves its trypsin- and chymotrypsin-in-
hibiting properties while decreasing its mucoadhesion. In turn,
immobilizing EDTA on chitosan prevents the secretion of
Zn-dependent peptidases. Employing thiomers, e.g. polycar-
bophil-cysteine, as compounds to inhibit enzyme action
enabled greater inhibitory polymer inﬂuence on the action of
carboxypeptidase A, carboxypeptidase B and chymotrypsin
(Bernkop-Schnurch, 2000). It was also proved that thiolated
polycarbophil had signiﬁcantly larger inhibitory inﬂuence than
unmodiﬁed polycarbophil on the activity of aminopeptidase
N. The apparently better carboxypeptidase A-, car-
boxypeptidase B- and aminopeptidase N-inhibiting properties
of modiﬁed polycarbophil may be also explained by the bind-
ing of Zn2+ ions in the enzyme structure, and were further
improved by connecting this polymer with L-cysteine
(Kawadkar and Chauhan, 2010). Employing thiomers and
inhibitor-polymer conjugates enables greater beneﬁts to be
obtained than in the case of traditional low molecular weight
drugs that inhibit enzymes due to the fact that these com-
pounds are not absorbed from the gastrointestinal tract and
are only covalently bound to the surface of non-absorbable
polymers; thus, they exhibit no toxicity. As a result of polymer
mucoadhesion, the inhibitor stays in contact with the absorp-
tion membrane for a longer period of time and the inhibitory
effects of its activity are localized (Kushawaha et al., 2010). In
the case of enzyme inhibition as a result of the complexation of
Table 4 Examples of polymeric enzyme-inhibitors (Vigl,
2009; Lv et al., 2014; Guggi and Bernkop-Schnurch, 2003).
Enzyme Polymeric inhibitor
Trypsin Polyacrylic acid, thiomers, polymer–enzyme–
inhibitor conjugates, sodium alginate
Chymotrypsin Polymer–enzyme–inhibitor
Elastase Polymer–enzyme–inhibitor
Exopeptidases Polyacrylic acid, thiomers, polymer–enzyme–
inhibitor conjugates
Nucleases Chitosan–aurintricarboxylic acid, chitosan–
EDTA, thiomers
530 B. Karolewiczessential metal ions, polymers can act without getting into
close contact with the target enzyme through the diffusion
mechanism. Examples of polymers with enzyme-inhibiting
properties can be found in Table 4.
Tardajos et al. also described the dose- and structure-de-
pendent inﬂuence of copolymers of sulfonated N-vinylpyrroli-
done with methyl maleate on their inhibiting activity on acidic
ﬁbroblast growth factor-mediated mitogenesis of ﬁbroblasts
(Tardajos et al., 2012).
5. Polymers enhancing the intestinal epithelium penetration
The intestinal epithelium constitutes a main barrier to the
absorption of peptide drugs. In order to decrease this barrier
function simultaneously with protein drugs, polymers to
enhance their penetration through mucosa are administered.
The strong effect of increasing drug penetration, obtained after
employing polymers, i.e. chitosan and carbomer, is accompa-
nied by a decrease in transepithelial resistance caused by the
loosening of tight junctions between the epithelium cells. The
exact mechanism of the thiolated polyacrylate activity is not
entirely explained, but it is probably based on the binding of
Ca2+ ions. Cationic ions, such as chitosan, can interact with
negatively charged residues on the cell surface, causing con-
formational changes in the structure of the membrane and pro-
teins tightly bound to its surface. The attachment of thiol
groups to a mucoadhesive polymer may additionally improve
their permeability-enhancing properties, which is explained
by inhibiting the action of the protein tyrosine phosphatase
(PTP), which through dephosphorylation of extracellular tyro-
sine group mediates in closing tight junctions. The effect is also
attributed to the covalent binding of the polymer to cysteine
residues (Vigl, 2009; Kawadkar and Chauhan, 2010).
Rambharose et al. (2014) examined the inﬂuence of multifunc-
tional excipients, i.e. polyacrylic acid, sodium alginate,
carboxymethyl cellulose, polyoxyethylene glycol, on the
permeability of pig mucosa to the antiviral drugs anionic teno-
fovir and cationic didanosine. For tenofovir, it was found that
drug penetration improved each time, whereas for cationic
didanosine, the increase in permeability was obtained only
through employing polyoxyethylene glycol. In another part
of their research, the focus was on analyzing the inﬂuence of
concentrations of polyoxyethylene glycol on the penetration
of both drugs. At 0.25–5% concentrations, an increase in both
substances penetration was recorded – for tenofovir the great-
est effect was achieved at 4% polymer concentrations, whereas
for didanosine it was 0.5% (Rambharose et al., 2014).It should be mentioned here that in comparison with other
groups of substances known to enhance drug penetration
through the intestinal epithelium, i.e. surface active agents,
fatty acids, salicylates or chelating agents, employing
multifunctional polymers is additionally advantageous due to
lack of their absorption and their remaining in high concentra-
tion in the target site.
6. Efﬂux pump-inhibiting polymers
The bioavailability of certain active substances after per os
administration is regulated and dependent, i.a., on the activity
of protein transporting drugs (Aleeva et al., 2009; Srivalli and
Lakshmi, 2012). These proteins remove them from the intesti-
nal epithelium cells back to the intestinal lumen. The best
known drug transporter is P-glycoprotein, present in the cell
membrane, which via the active transport mechanism
(‘‘pump’’) pumps out drugs from cells to extracellular spaces,
preventing their accumulation (Bernkop-Schnurch and
Grabovac, 2006; Bansal et al., 2009). P-glycoprotein has a wide
substrate speciﬁcity, recognizes many compounds of very dif-
ferent structures and physicochemical properties, of the 330–
4000 Da weight. The substrates for this protein are, i.a. drugs
with antineoplastic activity which act on the central nervous
system and cardiovascular system, and antimicrobial drugs
(Srivalli and Lakshmi, 2012). Inhibiting the activity of P-
glycoprotein through multifunctional polymers in the intesti-
nal epithelium cells may be the reason behind the decrease in
the transport of drugs to the intestinal lumen and thus they
contribute to the increase in their bioavailability. Due to
simultaneous administration of active substances with polysac-
charides such as xanthan gum, gellan gum, guar gum, agar,
tragacanth, sodium alginate, thiolated chitosan, thiolated
polycarbophil or chitosan-4-thio-butyl-amidine, the removal
of protein substrates drugs is prevented (Bernkop-Schnurch
and Grabovac, 2006; Bansal et al., 2009; Gaikwad and
Bhatia, 2013). The administration of paclitaxel in a carrier
designed on the basis of thiolated polycarbophil may serve
as an example. As a result of employing this polymer, an
increase of drug concentration in the blood plasma was
obtained and a decrease in the growth of a mammary tumour
in rats was noticed.
The polymeric inhibitors of P-glycoprotein also include
synthetic polymers, i.e. poloxamers, PEG, poly(lactide),
poly(D,L-lactide-co-glycolide) (PLGA), poly(caprolactone),
methoxypolyethylene glycol-block-polycaprolactone, polyoxy-
lates and dendrimers, as well as copolymers such as mPEG-
polycaprolactone, PEG-phosphatidylethanolamine, PEG-b-
PLA, mPEG-poly(caprolactone-trimethylene carbonate),
Eudragit S100 and dendrimers (Bernkop-Schnurch and
Grabovac, 2006; Bansal et al., 2009; Gaikwad and Bhatia,
2013; Mohammadzadeh et al., 2014; Zastre et al., 2007). One
example of their use is the improvement of penetration of gan-
ciclovir through the intestinal mucous membrane in rats,
which is classiﬁed as a BCS class III drug and was obtained
by using PEG and Pluronic F-68 and using PEG in studies
on verapamil penetration (Li et al., 2011).
Another activity that block copolymers from the poloxa-
mers group may inhibit, apart from that of P-glycoprotein, is
the activity of transporters such as MRP (multidrug resistance
proteins) and BCRP (breast cancer resistance proteins)
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Kabanov, 2008). Because of this, increases in bioavailability
and improvements to the therapeutic efﬁciency of antineoplas-
tic drugs, e.g. paclitaxel, are possible. It is thought that inhibit-
ing the activity of an ATP-dependent pump in this way is
caused by nonspeciﬁc changes in the conformation of lipids
and proteins and their mobility, and may additionally be a
result of inhibiting drug sequestration in an acidic environment
and detoxiﬁcation, with the participation of glutathione S-
transferase, due to the energy derived from the breakdown
of ATP. The ATP deﬁcit caused by the ATPase activity inhibi-
tion by copolymers may be the cause of a higher sensitivity of
the cells to the applied treatment (Batrakova and Kabanov,
2008).
7. Polymers of increased buffer capacity
Another feature of certain multifunctional polymers (i.e. chi-
tosan, polyacrylic acid) is their increased buffer capacity
(Vigl, 2009). Anionic and cationic polymers act like ion-ex-
change resins maintaining the constant pH value inside the
polymer network for a certain period of time. This may con-
tribute to the increase in stability of the incorporated drug,
limiting its pH-dependent denaturation or enzymatic degrada-
tion. Hydrated ionic polymers can maintain the pH value of
around 7, even in a gastric ﬂuid environment, thus protecting
the embedded macromolecular drugs from degradation. An
example of such a concept being applied is the use of a tablet
containing neutralized carbomer which is able to buffer the
drug inside a swollen matrix for several hours in an artiﬁcial
gastric ﬂuid with a pH value of 2. Similarly, in order to prevent
degradation of the substance in the intestine, polyacrylates in
their acidic form may be used (Bernkop-Schnurch, 2002).
This pH value also inhibits the activity of proteases, i.e. trypsin
and chymotrypsin, which are active only at pH values greater
than 4.8. Polymers with sorptive properties
Another advantage of using select polymers with multifunc-
tional properties, such as chitosan, is the possibility of using
them as substances with sorptive properties. In research studies
it was stated that polymers with a high molecular weight
adsorb lipid droplets better than polymers of a low molecular
weight. The reasons for this are due to the creation of different
shapes of cationic loops and tails and in the higher surface
activity of the chitosan particles of high weight. It should be
noted that different kinds of polymers bind different kinds of
bile acids with different strengths. The sorptive properties of
chitosan are attributed to the creation of a viscous polysaccha-
ride solution in a lipid environment and the presence of an
amine group in the structure of chitosan, facilitating the emer-
gence of electrostatic forces between the polymer and anionic
substances, i.e. fatty acids and bile acids (Rodriguez and
Albertengo, 2005; Ahmad et al., 2005).
9. Polymers with taste-masking ability
Copolymers of dimethylaminoethyl, butyl methacrylate and
methyl methacrylate have an ability to mask the taste ofadministered active substances, which is explained by the inﬂu-
ence of complementary ionic groups. Taste-masking is, then,
an effect of the interaction between cationic drugs and anionic
polymer, or vice versa. Randale et al. (2010) have designed fast
disintegrating tablets containing metoclopramide with the sub-
stance’s taste masked. They achieved this result through com-
plexing the drug in different ratios by extrusion method and
precipitation with aminoalkyl methacrylate copolymer
(Eudragit EPO). In the conducted tests, the drug-polymer
complex with a components ratio of 1:2 exhibited signiﬁcant
taste-masking, as conﬁrmed in the taste assessment by volun-
teers. These complexes turned out to possess a signiﬁcant
taste-masking ability with a degree of bitterness at or below
the threshold value (0.5) in 10 s, whereas the substance itself –
metoclopramide chlorhydrate – was assessed in the same
conditions as intensively bitter with a score of degree of bitter-
ness 3 for 10 s (Koo, 2011).
10. Polymers which interact with enzymes involved in drug
metabolism
Martin et al. (2013) examined the inﬂuence of ten polymers on
seven isoforms of cytochrome P450 (CYP450) using CYP450
enzymes derivatives of the entire concentration range. All
excipients caused noticeable activity effects – inhibiting or
increasing activity – on at least one CYP450 isoform, which
indicates that they have the potential to change pharmacoki-
netics of administered drugs. Table 5 presents the inﬂuence
of some polymers, i.e. poly(ethylene glycol) (PEG), Pluronic
F-68, Pluronic F-127, sodium carboxylmethyl cellulose
(NaCMC), hydroxypropyl cellulose (HPC), hydroxypropyl
methylcellulose (HPMC), poly(vinyl alcohol) (PVA),
Kollicoat, hydrolyzed gelatin (HG) and polyvinylpyrrolidone
30 K (PVP) on the activity of chosen isoforms of cytochrome
P450 (Martin et al., 2013).
11. Polymers with pharmacological activity
An interesting example of the properties of polymers is their
ability to inhibit the development of numerous viruses as well
as their immunostimulating, antibacterial, antioxidant and fat
absorption-decreasing activity.
Polyanionic compounds, i.e. sulphated polysaccharides
(dextrin-2-sulphate, carrageenan, dextran, cellulose sulphate)
may inhibit the growth of the HIV virus, herpes simplex virus
(HSV), cytomegalovirus (CMV) through limiting the absorp-
tion of viruses to the surface of host cells (Duncan, 2003;
Franz et al., 2000; Gyotoku et al., 1999; Neurath et al.,
2002; Shaunak et al., 1998; Campo et al., 2009; Schaeffer
and Krylov, 2000). Poly(amidoamine) (PAMAM) dendrimers
covalently modiﬁed with naphthyl sulfonate residues on the
surface exhibited antiviral activity against the HIV virus
(Svenson and Tomalia, 2005). A copolymer of divinyl ether
and maleic anhydride (DIVEMA) stimulates the creation of
glycoprotein, inhibiting the translation of viral RNA in cells
and the division of antineoplastic cells. The antibacterial activ-
ity of DIVEMA worked against both the Gram-positive and
Gram-negative bacteria and the antifungal activity of this
polymer worked against Cryptococcus neoformans, a species
of yeast that attacks mice lungs and brains (Popescu et al.,
2011; Oledzka and Sobczak, 2012; Munoz-Bonilla and
Table 5 Activity of the CYP450 enzyme after treatment with preparations containing polymers as excipients (Martin et al., 2013).
Polymer EC50a i (IC50)b (lM)
CYP2E1 CYP3A4 CYP3A5 CYP2C9 CYP2C19 CYP1A2 CYP2D6
PEG (75.3 ± 2.1) – (78.0 ± 17.8) (365.6 ± 32.8) (139.0 ± 22.4) – (409.6 ± 34.5)
Pluronic F-68 (203.7 ± 48.3) (59.1 ± 13.6) (209.9 ± 29.7) (244.8 ± 13.2) – – 387.6 ± 31.9
Pluronic F-127 (218.9 ± 13.3) 32.8 ± 11.8 – 355.0 ± 77.4 – – 101.6 ± 19.9
NaCMC – 12.6 ± 4.6 83.7 ± 17.3 113.2 ± 24.2 373.8 ± 68.2 (224.7 ± 14.8) –
HPC – – – – 89.5 ± 16.1 139.0 ± 4.0 148.3 ± 21.3
HPMC (253.5 ± 17.9) – (19.4 ± 0.6) – 211.8 ± 57.9 106.7 ± 23.1 159.3 ± 26.9
PVA (548.9 ± 30.4) – – – – – 354.8 ± 84.9
Kollicoat (598.1 ± 26.1) – – 259.8 ± 46.1 36.1 ± 1.8 (10.0 ± 3.9) (89.9 ± 2.9)
HG (141.2 ± 14.1) – – 249.5 ± 24.3 20.5 ± 5.3 (40.9 ± 8.4) 379.9 ± 22.3
PVP – (107.3 ± 11.2) – – – (78.3 ± 4.2) –
a Values without brackets – half maximal effective concentration (EC50).
b Values in brackets – half maximal inhibitory concentration (IC50). Lack of any entered values indicates lack of measurable effect. NaCMC –
sodium carboxymethyl cellulose; HPC – hydroxypropyl cellulose; HPMC – hydroxypropyl methycellulose; Kollicoat – copolymer poly)vinyl
alcohol)-graft-poly(ethylene glycol); HG – hydrolyzed gelatin.
Table 6 Activity of maleic anhydride copolymers (MA)
(Popescu et al., 2011).
Copolymer Activity
MA–2-cyclohexyl-1,3-dioxap-5-
ene
Antitumor activity,
immunostimulator, activation of
macrophages
MA–2-isopropenyl-1,3-dioxap-
5-ene
Antitumor activity
MA–ethylene Antitumor and antiviral activity
Maleic acid–acrylic acid Antitumor activity
MA–dihydropyran Antitumor activity
MA–dihydrofuran
MA–vinyl adenine Activation of macrophages
MA–styrene Inhibition of HIV-1 infection
(MA–styrene)-block-styrene
(MA–styrene)-block-styrene
derivatives with mannose or
glucose
MA–styrene Inhibitor of spermatozoa
motility, damaging the
spermatozoa membrane
Table 7 Inﬂuence of deacetylation degree and molecular
weight of chitosan on its antibacterial activity (Aranaz et al.,
2009).
Physico-chemical property Eﬀect on antimicrobial activity
› DD › Electrostatic binding to membrane
› Permeabilizing eﬀect
› Mw ﬂ Permeation into the cell nucleus
DD: deacetylation degree; Mw: molecular weight.
532 B. KarolewiczFernandez-Garcia, 2012). In Table 6, other, non-antiviral
activities of maleic anhydride copolymers are shown.
Antibacterial activities, which are explained by a change in
the properties of bacteria cell membranes, are also a feature of
chitosan (poly-D-glucosamine), its derivatives (chitooligosac-
charides COSs) and polypropylenimine (PPI) dendrimers with
tertiary alkyl ammonium groups attached to the surface
(Svenson and Tomalia, 2005; Aranaz et al., 2009; Cunha
et al., 2012). A positively charged amine group of glucosamine
units interacts with negatively charged components of the
membranes of Gram-negative bacteria and prevents the pass-
ing of nutrients into the cell interior or causes a leakage of
intracellular content. Another possible explanation of this
activity is that chitosan penetrates into the cell and binds with
DNA, which in turn inhibits of RNA transcription, and thus
leads to the inhibition of protein synthesis. The inﬂuence of
deacetylation degree and the molecular weight of chitosan dur-
ing its antibacterial activity is presented in Table 7 (Aranaz
et al., 2009; Cunha et al., 2012; Zheng and Zhu, 2003).
These polymers’ antibacterial activity, as well as the antiviral
activity against the HIV-1 virus, was also proved by adding
cellulose acetate phthalate (CAP) to the bacterial vaginosis
infection therapy. The result of the polymer’s activity is
explained by lowering the pH, buffering and hydrophobicity,
and the effect of the polymer remaining in micronized form
in the vaginal environment is similar to the activity of surface
active agent (Neurath et al., 2000). Only in this form, however,
does CAP have the ability to remove viruses from physiologi-
cal ﬂuids through their adsorption on the surface of micro-
nized particles (Neurath et al., 2002).
Chitosan may also have an antitumour activity which is
observed particularly in low-molecular-weight forms of poly-
mer (Aranaz et al., 2009). In an experiment carried out on
rodents, it was proved that partially acetylated chitosan inhi-
bits the growth of neoplastic sarcoma 180 cells. In in vitro
studies on HEK 293 and HeLa cell lines, the latter obtained
from cervical cancer cells, it was conﬁrmed that copper-chi-
tosan complexes obtained in different component ratios may
be employed as potential antineoplastic drugs (Zheng and
Zhu, 2003). Antiangiogenic properties are also possessed bydextrin-2-sulphate, which in patients with AIDS induced a
regression of Kaposi sarcoma (Duncan, 2003).
In the literature reports can be found of an antioxidant
activity of the low-molecular-weight chitosan, partially deacy-
lated. Although the mechanism of this activity is still
Table 9 Polymer–drug conjugates in clinical studies (Sanchis
et al., 2010).
Conjugate Company Status of
development
HPMA copolymer-Dox
PK1
Pﬁzer Inc., Cancer
Research Campaign,
UK
II
HPMA copolymer-Dox-
galactosamine PK2
Pﬁzer Inc., Cancer
Research Campaign,
UK
I/II
OxDextran-Dox AD-70 – I
PGA-CPT CT-2106 Cell Therapeutics
Inc.
I/II
Cyclodextrin-CPT IT-10 Cerulean I
Fleximer-CPT XMT-1001 Mersana I
HPMA copolymer-CPT
MAG-CPT
– I
PEG-CPT Pegamotecan Nektar II
Carboxymethyl-dextran-
exatecan DE-310
– I
PEG-irinotecan NKTR-102 Nektar II
HPMA copolymer-PTX
PNU 166945
Pﬁzer Inc. I
PGA-PTX CT-2103
(Opaxio)
Cell Therapeutics
Inc.
III
PEG-docetaxel NKTR-105 Nektar I
HPMA copolymer-
malonato-platinate AP5280
Access
Pharmaceuticals Inc.
I
HPMA copolymer-DACH-
platinate AP5346
(ProLindac)
Access
Pharmaceuticals Inc.
II
HPMA: N-(2-Hydroxypropyl)methacrylamide; OxDextran: Oxi-
dized dextran; CPT: Camptothecin; DACH: Diaminocyclohexane;
Dox: Doxorubicin; PEG: Poly(ethylene glycol); HPMA: N-(2–2-
hydroxypropyl)methacrylamide; PGA: Poly-l-glutamic acid; PTX:
Paclitaxel.
Table 8 Inﬂuence of deacetylation degree and molecular
weight of chitosan on binding and metabolism of fats (Aranaz
et al., 2009).
Physico-
chemical
property
Eﬀect in vitro Eﬀect in vivo
› DD › Electrostatic force between
chitosan and fatty and bile
acid
ﬂ Plasma
cholesterol
ﬂ LDL
› HDL
› Mw › Adsorption to lipid droplets
ﬂ adsorption to droplet
surface of lipase
ﬂ Body weight
gain
ﬂ Adsorption and
blood distribution
ﬂ Liver total lipid
and cholesterol
DD: deacetylation degree; Mw: molecular weight; LDL: low den-
sity lipoprotein; HDL: high density lipoprotein.
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amine group and hydroxyl groups in the respective positions
C-2, C-3 and C-6, which react with free radicals, thus creating
more stable macromolecular radicals. A second reason may be
the chelation of iron ions, which is why chitosan is considered
as a potential natural antioxidant (Aranaz et al., 2009).
There are also reports of chitosan and its oligomers display-
ing hemostatic and antithrombogenic activities, which have
been conﬁrmed in in vitro tests. The anticoagulant activity of
chitosan seems to be an effect of binding the positively charged
polymer to the membranes of negatively charged red blood
cells (Aranaz et al., 2009; Cunha et al., 2012; Ray, 2011).
Microcrystalline chitosan with a molecular weight 103–106
and deacetylation degree of 60–100%, obtained through the
modiﬁcation of chitosan by the method of aggregation, in turn
has platelets reactivity decreasing properties, thus lowering the
risk of vascular occlusions, which is proved by inhibiting the
release of P-selectin from a-granules of the platelets and
the inhibition of Iba internalization.
Some researchers have stated that chitosan exhibits anal-
gesic activity. Results suggest that the main reason for this
effect is the absorption of positively charged ions that are
released in the inﬂammation area. Due to their polycationic
nature, free amine groups of chitosan may be protonated in
the presence of cations and, as a result, may lower the pH level,
which is the main reason for the polymer’s analgesic activity
(Aranaz et al., 2009).
The anti-cholesterol activity of chitosan was also described
and its mechanism may be explained in two ways. On one
hand, it may be caused by creating a viscous solution of
polysaccharide, thus decreasing the absorption of fat and
cholesterol from the diet; on the other hand, it could be due
to the presence of an amine group in chitosan structure, which
facilitates the emergence of electrostatic forces between the
polymer and anionic substances, i.e. fatty and bile acids.
Another possible mechanism theory involves the assumption
of chitosan adsorption to the lipid emulsions surface and the
creation of a protective layer (Aranaz et al., 2009; Cunha
et al., 2012; Ray, 2011). The inﬂuence of the deacetylation
degree and molecular weight of chitosan on the binding and
metabolism of fats is presented in Table 8. Hipolipidemic
activity is also attributed to carrageenans (campo et al., 2009).
The anti-inﬂammatory effects of chitosan and its deriva-
tives, as well as their antidiabetic, neuroprotective, immune
system-stimulating and antibacterial activity in the prevention
and treatment of periodontal disease, have also been docu-
mented in the literature (Cunha et al., 2012) (see Table 9).
Olendzka et al. described the hydrochloric acid-neutralizing
effect obtained after employing a linear polymer of uronic
acids – alginic acid (mannuronic acid conjugated b-1,4 and
L-guluronic acid glycosidically conjugated a-1,4). This polymer
retains water in the stomach, thus decreasing irritation and
pain. Another polymer, polyvinylpyrrolidone, is in turn
employed as substance with antidiarrhoeal effects. Its ampho-
teric properties enable pH normalization in the stomach and
intestines through adsorption of acids and bases, which usually
form as a result of fermentation and decomposition (Oledzka
and Sobczak, 2012).
Sulfated glycosaminoglycans (GAGs), i.e. dextran sulphate,
gellan sulphate and fucosylated chondroitin sulphate, possess
properties inhibiting the growth of Plasmodium falciparum byinhibiting the invasion of merozoites into erythrocytes in
in vitro conditions. Dextran sulphate and fucosylated
chondroitin sulphate prevent the cytoadherence of
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phate mechanism has been studied in order to explain whether
it inhibits parasite adhesion to red blood cells similar to other
glycosaminoglycans (Recuenco et al., 2014).12. Polymer–drug conjugates
Polymer–drug conjugates are obtained on the basis of biocom-
patible macromolecular compounds connected covalently,
usually with biologically active molecules, i.e. peptides and
proteins of low macromolecular weight. This connection
enables the improvement of their solubility, stability or
decreasing immunogenicity. In most cases, the polymer’s pres-
ence increases the solubility of a hydrophobic drug and
improves its pharmacokinetic proﬁle, causing the extension
of drug’s half-life time in the blood plasma while simultane-
ously increasing the volume of distribution and decreasing
the renal and hepatic clearance. The polymer protects the drug
from degradation and may actively participate in its release in
speciﬁed conditions controlled through pH changes or the
presence of enzymes. Polymers employed as components
of designed conjugates include: polyoxyethylene glycol,
b-cyclodextrin, dextran, poly(c-glutamic acid), polyacrylic
acid, poly (styrene – maleic acid), poly(a-glutamic acid),
poly(dimethylamino) ethyl methacrylate (pDMAEMA), N-[2-
hydroxypropyl]methacrylamide and poly-K8-(VPGXG)60
(VPGXG: Valine-proline-glycine-X-glycine) (Pasut and
Veronese, 2007; Vilar et al., 2012).
Progress in the development of synthesis methods and poly-
mer chemistry resulted in polymer–drug conjugates at ﬁrst
employed in cancer therapy, and then in the treatment of other
diseases, i.e. diabetes, hypertension, infections, gastrointestinal
tract diseases or rheumatoid arthritis (RA). Currently, in clini-
cal trials, the efﬁcacy of 14 designed conjugates containing
antineoplastic active substances is being conﬁrmed. The most
advanced studies are conducted on the Opaxio conjugate,
which is obtained by connecting poly-L-glutamic acid to pacli-
taxel and is expected be employed in the near future as a poten-
tial drug in the therapy of ovarian cancer, non-small cell lung
cancer and esophageal cancer (Duncan, 2003).
Drug-PEG conjugates are widely described in the literature.
They are passively targeted into neoplastic tumours – this phe-
nomenon is known as the enhanced permeability and retention
effect (EPR). Such effect involves the passive accumulation of
substances, usually liposomes or macromolecular drugs, in the
tumour tissue, caused by a lack of efﬁcient lymphatic drainage
in a solid tumour and its increased vascular permeability
resulting from endothelial discontinuity (Kim et al., 2009).
The design of c-PGA-PRZ connections containing phlo-
ridzin (PRZ), classiﬁed as SGLT1 protein, constituting a new
class of oral antidiabetic drugs inducing glycosuria, is an
example of how conjugates have been used in the treatment
of diabetes. These proteins constitute a group of sodium-de-
pendent glucose cotransporters responsible for glucose absorp-
tion in the gastrointestinal tract and its renal reabsorption.
Due to toxicity, these substances are not administered orally.
However, the c-PGA-PRZ conjugate, because of its high
molecular weight, is not absorbed in the small intestine and
may be administered via this route. Moreover, the spatial
structure of the polymer chain also protects the drug from
hydrolysis. After the oral administration of conjugates, asigniﬁcant improvement in pharmacological effects and drug
toxicity reduction were obtained in comparison with unmodi-
ﬁed substance (Sanchis et al., 2010).
In order to improve the solubility in water of 4-amino-6-hy-
droxypyrazolo[3,4-d]pyrimidine (AHPP), an inhibitor of the
xanthine oxidase enzyme, it was conjugated with biocompati-
ble amphiphilic polymer – a styrene maleic acid copolymer
(SMA), thus enabling it to obtain connections that are highly
soluble in water. The SMA-AHPP conjugate in in vivo studies
conducted on animals exhibited a longer action than that of
free AHPP. After oral administration of the modiﬁed drug,
blood pressure in the examined group remained low compared
to the control group for up to 168 h. Considering the action
mechanism of SMA-AHPP towards the xanthine oxidase
enzyme, there is a possibility of employing this conjugate in
the therapy of other diseases involving the presence of perox-
ides, e.g. viral infections, ulcers, inﬂammatory diseases and
ischaemia/reperfusion injuries, as well as in pathological states
connected with the forming of peroxynitrite anion (ONOO–),
which mediates the cytotoxic effect (Sanchis et al., 2010).
Other antiviral HIV-1 protease inhibitor conjugates –
saquinavir (SQV) and polymer – were obtained by forming
ester bond between them, due to which the drug solubility
improved and its half-life time was extended. Vlieghe et al.
conjugated azidothymidine (AZT) with j-carrageenan, con-
ﬁrming in in vitro studies on MT-4 cells an enhanced antiviral
activity of obtained conjugates compared with the free drug
(Vlieghe et al., 2002). After administrating other conjugates
of azidothymidine with dextran, the drug concentration in
blood plasma remained on the level of inhibiting concentra-
tion, IC50, for up to 30 h, whereas for free drug this concentra-
tion fell to an undetectable level after just 5 h. To sum up,
employing conjugates limits the ﬂuctuations of AZT plasma
concentrations, thus decreasing its toxicity, or, as in the case
of conjugates of AZT with a,b poly(N-hydroxyethyl)-DL-
aspartamide (PHEA), enables controlled drug release
(Giammona et al., 1999).
Using amphotericin B (AMB) in mycoses therapy is limited
due to its poor solubility in water and high nephrotoxicity. In
order to take advantage of the acid environment which accom-
panies the fungal infections, PEG-AMB conjugates which
selectively release the drug in an infection area in acid pH were
used in the therapy (Sanchis et al., 2010).
PEG-naloxone (NKTR-118) conjugates have also been
researched – they are currently in Phase II of clinical trials
and are intended for the therapy of opioid-induced constipation
or for the treatment of other intestinal dysfunctions resulting
from administering these substances. The purpose of forming
NKTR-118 conjugates was to decrease the side effects of opioid
therapy and to enhance the activity of peripheral opioid recep-
tors, while simultaneously avoiding drug permeability across
the blood–brain barrier and side effects on the central nervous
system (CNS). Phase I of clinical trials conﬁrmed good toler-
ance of the drug, its fast absorption and longer half-life time
compared with free naloxone (Pasut and Veronese, 2009).
In order to improve the effectiveness of ulcerative colitis
treatment with the use of corticosteroids, Varshosaz et al. syn-
thesized dextran-budesonide conjugates. The in vitro studies
on the stability of obtained conjugates in an acid environment
and in phosphate buffers of different pH values, as well as in
in vivo studies, conﬁrmed that less than 10% of conjugates
were subjected to pH hydrolysis in the stomach and ﬁrst
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tration was achieved as a result of microﬂora activity in the
caecum and colonic (Varshosaz et al., 2009).
Employing polymeric conjugates in the process of tissue
repair, wound healing, bone resorption or ischaemia/reperfu-
sion injuries also seems very promising (Sanchis et al., 2010).
13. Conclusion
Polymers in pharmaceutical technology constitute an impor-
tant class of excipients of constantly increasing signiﬁcance;
therefore, discovering their properties becomes vital.
Multifunctional polymers constitute a group of compounds
which, apart from their basic functions, may additionally play
an important role in formulating intelligent drug delivery sys-
tems, thus contributing to the improvement of achieved thera-
peutic effect. The use of polymer properties described in this
review should be considered when selecting desired excipients
for new formulations.Founding source
Nil.
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